Small biotech says its Covid-19 vac­cine spurs more an­ti­bod­ies than As­traZeneca’s. Will sup­ply deals come now?

In a first, a small run­ner-up vac­cine de­vel­op­er says its own Covid-19 jab has in­duced “su­pe­ri­or neu­tral­iz­ing an­ti­body titer lev­els” over As­traZeneca’s AZD1222 when pit­ted …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER